The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT06030843

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Chulalongkorn University (from the registry)
Registry
  • NCT NCT06030843
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Thailand (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06030843. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-01 (actual); primary completion 2026-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Acronym
TREAT-CRS
Condition
Empagliflozin in Cardiorenal Syndrome Type 1
Intervention (Drug)
Empagliflozin 10 MG
Intervention (Drug)
Placebo
Lead sponsor
Chulalongkorn University (class: other)

Record details

Record id
cardio:ct-nct06030843
Content hash
baaeda5d12051dc0319bca60b09ea6ff5f75727a3f5ef56d5b169b86a6b0ed5c